Last reviewed · How we verify
NCT06299254: POF
Placebo Effect About Fatigue in Obesity
trial testing Placebo-Natural History in Obesity in 80 participants. Completed in 28 February 2025.
28 February 2025
Quick facts
| Lead sponsor | Istituto Auxologico Italiano |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 March 2023 |
| Primary completion | 28 February 2025 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Placebo-Natural History
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Istituto Auxologico Italiano — full company profile →
Who can join
Adults 20 to 50, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fatigue is a central symptom of obesity: it significantly impacts daily functioning, psychological well-being, compliance with physical therapy, and quality of life. However, the full understanding of the origin and treatment of fatigue in obesity is still a matter of debate, requiring further research, especially from new perspectives. From a neuroscientific perspective, fatigue is more than the subjective perception of tiredness resulting from mental or physical exertion or illness. It results in the complex interaction between (bottom-up) sensory input coming from the periphery, and motivational and psychological input, which is related to top-down cognition. In this framework, placebos may affect the output of the top-down cognitive processing by altering the individual evaluation of the ongoing peripheral performance. Indeed, evidence from both healthy conditions and clinical contexts suggests that fatigue can be modulated. The after-effect of such a modulation can be observed not only at a behavioural level, in terms of physical endurance, but also a psychological (i.e., decreased of perceived fatigue) and neurophysiological (changes in brain activity, especially in the fatigue-related components as the RP) levels.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Motor placebo effect in obesity: how ergogenic aids can decrease fatigue and improve motor performance.
Volpino V, Navarra ME, Scarpina F, Piedimonte A, et al · · 2025 · PMID 41212312 · DOI 10.1007/s40519-025-01794-5
Verify or expand the search:
- PubMed search for NCT06299254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Istituto Auxologico Italiano trials
Trials by the same sponsor.
- NCT07384962 — ORION Study: Mesh Position and Risk During Subsequent Minimally Invasive Abdominal Surgery · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07302321 — Needs of ALS Patients With C9orf72 Mutation and Their Caregivers · recruiting
- NCT07162740 — Implantable Loop Recorder and Cardioneuroblation · not yet recruiting
- NCT07312240 — LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06299254 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Auxologico Italiano
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06299254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing